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ARTICLE
Molecular Dissection of Isolated Disease Features in Mosaic
Neuroﬁbromatosis Type 1
Ophe´lia Maertens, Soﬁe De Schepper, Jo Vandesompele, Hilde Brems, Ine Heyns, Sandra Janssens,
Frank Speleman, Eric Legius, and Ludwine Messiaen
Elucidation of the biological framework underlying the development of neuroﬁbromatosis type 1 (NF1)–related symptoms
has proved to be difﬁcult. Complicating factors include the large size of the NF1 gene, the presence of several NF1
pseudogenes, the complex interactions between cell types, and the NF1-haploinsufﬁcient state of all cells in the body.
Here, we investigate three patients with distinct NF1-associated clinical manifestations (neuroﬁbromas only, pigmentary
changes only, and association of both symptoms). For each patient, various tissues and cell types were tested with
comprehensive and quantitative assays capable of detecting low-percentage NF1 mutations. This approach conﬁrmed
the biallelic NF1 inactivation in Schwann cells in neuroﬁbromas and, for the ﬁrst time, demonstrated biallelic NF1
inactivation in melanocytes in NF1-related cafe´-au-lait macules. Interestingly, both disease features arise even within a
background of predominantly NF1 wild-type cells. Together, the data provide molecular evidence that (1) the distinct
clinical picture of the patients is due to mosaicism for the NF1 mutation and (2) the mosaic phenotype reﬂects the
embryonic timing and, accordingly, the neural crest–derived cell type involved in the somatic NF1 mutation. The study
of the affected cell types provides important insight into developmental concepts underlying particular NF1-related
disease features and opens avenues for improved diagnosis and genetic counseling of individuals with mosaic NF1.
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Neuroﬁbromatosis type 1 (NF1 [MIM 162200]) is a com-
mon autosomal dominant disorder caused by alterations
in the NF1 gene. The NF1-encoded protein, neuroﬁbro-
min, functions as a negative regulator of Ras-mediated
signaling.1–3 The primary clinical features of NF1 are cafe´-
au-lait macules (CALMs), freckling, and benign peripheral
nerve sheath tumors or neuroﬁbromas.4 Patients withNF1
also have a predisposition to develop a wide spectrum of
other symptoms, illustrating the critical function of neu-
roﬁbromin in a variety of tissues and cell types. The bi-
ological context underlying the development of many
NF1-related symptoms and complications, however, re-
mains incompletely understood.
Mosaic NF1 is caused by a postzygotic NF1 lesion5–7 and
can present as mild generalized disease, segmental disease,
or gonadal mosaicism.8 Revertant mosaicism, as reported
to be caused by a postzygotic back mutation in some dis-
orders,9 has not yet been described in cases of NF1. The
mosaic phenotype most probably reﬂects the timing of
the somatic mutation and some of the tissues affected by
it. Since segmental NF1 is characterized by the regionally
limited distribution of NF1 disease signs, it provides the
opportunity to study cell populations differing only with
regard to the mutation(s) giving rise to mosaicism. De-
termining when and in what cell types inactivation of the
NF1 gene occurs is critical for understanding the basic
pathology of NF1-related symptoms.
In this study, we investigated one patientmildly affected
with NF1 and two patients with segmental NF1. The three
patients had different clinical manifestations—that is,
neuroﬁbromas only, pigmentary changes only, and a com-
bination of both neuroﬁbromas and pigmentary changes.
To elucidate the involvement of particular cell types and
mutational mechanisms in the respective phenotypes, we
investigated various tissues and cell types from every pa-
tient with mosaic NF1 with quantitative assays capable of
detecting low-percentage NF1 mutations.
Material and Methods
Patient Material
Three patients with distinct NF1-associated clinical manifesta-
tions were included in the study.
Neuroﬁbromas only.—Patient SNF1-1 is a 46-year-old woman
who has several small (1–4 mm) cutaneous neuroﬁbromas clus-
tered within a limited body region on her trunk and neck. At a
given time, 35–40 neuroﬁbromas were present. Several tumors
have been removed during different sessions, and three were
available for this study. She also underwent surgery for an intes-
tinal ganglioneuroma (S100 and neuroﬁlament positive; c-Kit
negative). Careful examination did not reveal freckling or local-
ized hyperpigmentation. Only three hyperpigmented spots small-
er than 2 cm were present. She had no Lisch nodules, no learning
disabilities, and no other signs of NF1 except for a glomus tumor
at the distal phalanx of the right middle ﬁnger. Her height is 164
cm, and there was no clinical evidence of macrocrania. Her par-
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Figure 1. Illustration of clinical subtypes of patients with mosaic NF1. A, Patient SNF1-2 presented with several CALMs (arrows) within
a pigmented background involving the entire right leg, hip, and lower back (outlined). B, Patient SNF1-3 presented with more than six
CALMs (one outlined on the left) scattered over the body and several small neuroﬁbromas (asterisks) located on the right hand within
an overlying CALM (outlined on the right).
ents and her two sons (aged 20 and 23 years) don’t show any
NF1-related symptoms. Peripheral blood from the patient and her
sons, as well as the patient’s buccal smears, hair roots, urine,
Schwann cells, and ﬁbroblasts cultured from threeneuroﬁbromas,
were available for analysis.
Pigmentary defects only.—Patient SNF1-2 is a 23-year-old man
presenting with several CALMs within a background of hyper-
pigmented skin involving his entire right leg, hip, and lower back
(ﬁg. 1A). Inguinal freckling was present in the affected segment.
No hyperpigmentation or CALMs were revealed outside the de-
scribed area. Careful examination of his entire body did not reveal
any neuroﬁbromas. Ophtalmological examination ﬁndings were
negative for Lisch nodules. His height is 182 cm, and his head
circumference is 58 cm. He has no learning disabilities; currently,
he is a high school student. He does not have children, and his
parents do not show any NF1-related symptoms. Peripheral
blood, buccal smears, hair roots, and urine sediment cells were
available for investigation, as were ﬁbroblasts and melanocytes
cultured from normal skin, CALM, and the hyperpigmented area.
Pigmentary defects and neuroﬁbromas.—Patient SNF1-3 is a 15-
year-old girl with more than six CALMs scattered over her body
and several small cutaneous and subcutaneous neuroﬁbromas
located on her right hand within an overlying CALM (ﬁg. 1B).
CALMs (11.5 cm) not occurring within regions of hyperpig-
mented skin are located on her right lower back (two), right arm
(one on the front [ﬁg. 1B] and one on the back), left wrist (one),
left thigh (one), left ankle (one), left gluteal region (one), right
calf (one), right thigh (two), and right groin (two). Total-body
nuclear magnetic resonance imaging (MRI) revealed a putative
neuroﬁbroma on her left shoulder. Physical examination did not
reveal skinfold freckling or any other signs of NF1. Her height is
163.5 cm, and her head circumference is 55 cm. She does not
have learning disabilities, and her parents do not show any NF1-
related symptoms. Peripheral blood, buccal smears, hair roots,
and urine sediment cells, together with Schwann cells and ﬁbro-
blasts derived from one subcutaneous neuroﬁbroma and ﬁbro-
blasts and melanocytes derived from three CALMs (on her right
hand, left thigh, and right lower back) and from normal skin
(right buttock), were available for analysis. MRI of the patient’s
right hand revealed a subcutaneous nodule with a few smaller
surrounding subcutaneous satellite lesions. Histopathologically,
the lesions were determined to be neuroﬁbromas by the absence
of mitotic activity and the mixture of elongated spindle-shaped
Schwann cells and ﬁbroblasts in a background of wavy collage-
nous ﬁbers. This diagnosis was conﬁrmed by immunohistochem-
istry (S100 positivity in the majority of spindle-shaped cells).
Cell Culture
Skin biopsy.—A sample of normally pigmented and/or hyper-
pigmented skin was taken using 5-mm punch biopsy excision.
To separate the epidermal layer (with melanocytes anchored to
the basal membrane) from the underlying dermis (with ﬁbro-
blasts), skin biopsy samples were incubated overnight at 4C in
dispase II (Boehringer Mannheim). Primary epidermal melano-
cyte cultures from the skin biopsy samples were established as
described elsewhere.10 In brief, melanocytes were cultured in
Ham’s F10 medium (Gibco, Invitrogen) supplemented with 2.5%
fetal calf serum (FCS), 1%Ultroser, 5 ng/ml basic ﬁbroblast growth
factor, 10 ng/ml endothelin-1, 0.33 nM cholera toxin, 0.033 mM
isobutyl-methyl-xanthine, 5.3 nM 12-O-tetradecanoyl phorbol-
13-acetate, and 20 ng/ml stem cell factor (SCF). Dermal ﬁbroblasts
were grown in Dulbecco’s modiﬁed Eagle medium (Gibco, Invi-
trogen) supplemented with 10% FCS.
Neuroﬁbroma.—Culture conditions for neuroﬁbroma-derived
Schwann cells and ﬁbroblasts were as described elsewhere.11,12 The
presence of forskolin (F) in the Schwann cell medium promotes
proliferation of cells bearing only the ﬁrst hit (NF1/, SC F).
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Replacement of proliferation medium by serum-free N2 medium
and, subsequently, by proliferationmediumwithout forskolin (F)
promotes proliferation of cells containing both hits (NF1/). To
estimate the purity of Schwann cell and ﬁbroblast culturesderived
from the neuroﬁbroma of patient SNF1-3, immunoﬂuorescence
staining with rabbit S100 primary antibody (Dako)was performed
as described elsewhere.13 For one SC F culture (patient SNF1-1,
neuroﬁbroma 3), Schwann cells were separated from contami-
nating ﬁbroblasts by the use of p75 (nerve growth factor recep-
tor)–coupled Magnetic Cell Sorting Microbeads (Miltenyi Biotec),
which magnetically label the Schwann cell target population.
Subsequent growth of recovered cells in Schwann cell medium
resulted in a highly pure Schwann cell culture (195%, estimated
by S100 staining).
NF1 Mutation Screening
NF1 mutation analysis (GenBank reference sequence NM_000267)
was performed essentially as described elsewhere.14 In brief, ge-
nomic DNA (gDNA) was extracted from melanocyte cultureswith
the QiaAmp procedure (Qiagen) and from all other cell cultures
with the Puregene procedure (Gentra). Cultures were treated with
puromycin (200 mg/ml for 4–6 h) before RNA extraction (RNeasy
kit [Qiagen]). The entire NF1 cDNA was sequenced using the
ABI3730XL genetic analyzer (Applied Biosystems). All mutations
found at the cDNA level were conﬁrmed in gDNA by cycle se-
quencing. Multiplex ligation-dependent probe ampliﬁcation
(MLPA) analysis was performed using the SALSA NF1 area kit
(MRC Holland), in accordance with the manufacturer’s instruc-
tions, to detect deletions.
Fine Mapping NF1 Deletion Breakpoints
The genomic deletions detected by MLPA analysis were evaluated
in further detail. The location of the NF1 microdeletion break-
points was determined by aspeciﬁcally amplifying and sequenc-
ing paralogous sequence variants (PSVs) in the low copy repeats
(LCRs) ﬂanking the NF1 microdeletion region.15 By scoring the
relative intensity of both nucleotides of the PSV, the location of
the breakpoint was determined to be centromeric (higher relative
intensity of the nucleotide speciﬁc to the telomeric LCR) or telo-
meric (higher relative intensity of the nucleotide speciﬁc to the
centromeric LCR) of the PSV investigated.
Loss of Heterozygosity in NF1 Region
Loss of heterozygosity (LOH) in the NF1 gene region was eval-
uated by genotyping two microsatellite markers telomeric of (3′
NF1-3 and 3′ NF1-1)16 and four within the NF1 gene (Alu,
IVS27AC33.1, IVS38GT53.0, and IVS27TG24.8).17–20 gDNA from
paired melanocyte/Schwann cell and lymphocyte cultures from
the same patient was investigated by touchdown PCR for the
microsatellite markers (PCR program starting at 62C, gradually
reduced [1C/cycle] to 50C for an additional 25 cycles) and was
subsequently analyzed on the ABI3130XL genetic analyzer (Ap-
plied Biosystems) with GeneMapper software version 3.7 (Applied
Biosystems). To determine the extent of LOH in different samples
from patient SNF1-3, additional SNPs proximal (rs6505129,
rs6505165, and rs8071580) and distal (rs9904537 and rs753750)
to the NF1 microdeletion region were evaluated as described else-
where.21 LOH for a SNP was scored when the average ratio (SNP
nucleotide:control nucleotide) of the two alleles in the tested
tissue fell outside the 95% CI of the ratios observed in control
blood DNA of the same patient and when the average ratios in
tested tissue versus control blood were at least 20% different. The
mechanism underlying LOH (deletion vs. mitotic recombination)
was evaluated by semiquantitative PCR, which took advantage
of the ampliﬁcation of NF1 exon 22 (103 bp) together with the
corresponding fragment of its pseudogene located on chromo-
some 15 (107 bp), as described elsewhere.21
Cloning NF1 Point Mutations
To determine whether both NF1 mutations detected in SC F
cultures derived from the neuroﬁbromas of patient SNF1-1 re-
sided on different alleles, cloning experiments were performed.
For neuroﬁbroma 1 (NF1 c.2041CrT and c.1655TrG), a fragment
containing both alterations and an additional SNP in exon 13
(rs2285892) was ampliﬁed (516 bp), cloned in the pCR2.1-TOPO
Vector (Invitrogen), and sequenced. For neuroﬁbroma 2 (NF1
c.2041CrT and c.603_621delinsC), a fragment containing the
deletion and a SNP in exon 5 (rs1801052) was ampliﬁed (286 bp),
cloned, and sequenced. Since rs1801052 and rs2285892 are in
complete linkage disequilibrium, information on the genotype
of the SNP in exon 13 linkedwith the ﬁrst hit (cloning experiment
neuroﬁbroma 1) and information on the genotype of the SNP in
exon 5 linked with the second hit (cloning experiment neuro-
ﬁbroma 2) provide information regarding whether both muta-
tions reside on the same (exon 5/exon13: A/G or G/A) or different
(exon5/exon13: A/A or G/G) haplotypes.
Quantiﬁcation of NF1 Mutations
Real-time quantitative PCR.—To detect low-percentagemosaicism
for NF1 point mutations against a background of normal and
pseudogene alleles, a nested real-time quantitative PCR (qPCR)
assay was developed.22 In brief, the region spanning theNF1point
mutation was ampliﬁed (primer sequences available on request),
and equimolar dilutions of cloned PCR fragments (wild-type and
mutant alleles) were used to generate standard curves of 5 orders
of magnitude. For actual quantiﬁcation, allele-speciﬁc 3′ locked
nucleic acid primers (Eurogentec) were used. Since both somatic
NF1 point mutations appeared to be present in several NF1 pseu-
dogenes, samples were ﬁrst ampliﬁed with NF1 speciﬁc primer
pairs and were diluted prior to nested real-time qPCR. Real-time
qPCR reactions were performed on an iCycler iQ instrument (Bio-
Rad). In each experiment, duplicates of a standard dilution series
of speciﬁc PCR fragments for each allele variant (wild-type and
mutant) and triplicates of 10 ng DNA of unknown samples (dif-
ferent tissues from patient withmosaic NF1 under study andnon-
NF1 control sample) were ampliﬁed in a 15-ml reaction containing
1# SYBR Green I Master Mix (Eurogentec) and 250 nM of allele-
speciﬁc primers. The thermal proﬁle consisted of 1 cycle at 95C
for 10 min followed by 40 cycles at 95C for 15 s and at 61C or
63C for 1 min. Each experiment was performed twice, and data
acquisition and automated analysis was done by the iCycler iQ
software version 3.1 (Bio-Rad). The relative number of molecules
of each allele was determined by interpolating the threshold cycle
values of the unknown samples to each standard curve, followed
by the determination of the fraction of mutant alleles (number
of mutant molecules divided by the sum of the number of wild-
type and mutant molecules).
FISH analysis.—Submicroscopic NF1 deletions were scored us-
ing dual-color FISH23 with PAC clones 22 (RP5-926B9; 5′ NF1) and
13 (RP5-1002G3; 3′ NF1).16 To investigate mosaicism, at least 400
246 The American Journal of Human Genetics Volume 81 August 2007 www.ajhg.org
Table 1. Overview of NF1 Mutations Revealed by Routine
Mutation-Detection Techniques and Real-Time qPCR in
Different Tissues Derived from Segmental Patient SNF1-1,
Presenting with Neuroﬁbromas Only, and from Two Sons
Patient
and Samplea
c.2041CrT (p.R681X)
Second HitRoutine qPCRb
SNF1-1:
Neuroﬁbroma 1:
SC F  41.4%6.4% c.1655TrG (p.L552R)
Fibroblasts  8.4%.5% 
Neuroﬁbroma 2:
SC F  47.4%8.6% c.603_621delinsC
Fibroblasts  19.4%5.5% 
Neuroﬁbroma 3:
SC F  6.7%1.0% 
Fibroblasts   
Blood  3.7%.4% 
Buccal smear   
Urine   
Hair  1.8%.3% 
Child 1:
Blood   
Child 2:
Blood   
NOTE.— p Mutation detectable;  p mutation not detectable.
a SC F p Schwann cells grown without forskolin.
b Percentage of mutant alleleSEM determined by real-time qPCR.
Table 2. Overview of NF1 Mutations Revealed by
Routine Mutation-Detection Techniques and FISH
Analysis in Different Tissues Derived from
Segmental Patient SNF1-2, Presenting with
Pigmentary Defects Only
Sample
NF1
Microdeletion
Second HitRoutine FISHa
CALM:
Melanocytes  ND c.1226_1227del
Fibroblasts  !7% 
Hyperpigmentation:
Melanocytes  ND 
Fibroblasts  !7% 
Unaffected skin:
Melanocytes  ND 
Fibroblasts  !7% 
Blood  2% 
Buccal smear  ND 
Urine  ND 
Hair  ND 
NOTE.— p Mutation detectable;  p mutation not
detectable.
a Percentage of 400 interphase nuclei with NF1 micro-
deletion determined by FISH analysis. ND p no data
available.
interphase nuclei were evaluated. By analysis of control samples
derived from patients not affected with NF1, the sensitivity of
the assay was estimated at 1% for lymphocytes and 7% for
ﬁbroblasts.
Results
Neuroﬁbromas Only (Patient SNF1-1)
NF1 mutation screening of selectively cultured Schwann
cells (SC F) revealed an identical mutation (c.2041CrT
[p.R681X]) in two different neuroﬁbromas. In addition,
two tumor-speciﬁc alterations (c.1655TrG [p.L552R] and
c.603_621delinsC) were detected. Cloning experiments
demonstrated that both NF1 mutations (common and tu-
mor speciﬁc) resided on different alleles. Quantiﬁcation
ofmutant transcripts in the presence of thewild-type form
was tested by mixing an excess (5#105 molecules) of wild-
type allele with a 5-point 10-fold dilution series of the
mutant form (5#105—50 molecules). As a control, a stan-
dard curve containing only the mutant transcript was
used. Ideally, both series should result in overlapping am-
pliﬁcation plots. We observed, however, that, at low levels
of mutant transcript (!2,500 molecules), the presence of
the wild-type transcript (5#105 molecules) signiﬁcantly
impaired accurate quantiﬁcation of the low-abundance
mutant transcript. Therefore, the sensitivity of the quan-
titative assay is estimated at 1/200. Real-time qPCR dem-
onstrated the presence of the ﬁrst hit (mutant allele per-
centageSEM) in Epstein Barr virus–transformed white
blood cells (3.7%.4%), hair follicles (1.8%0.3%), ﬁ-
broblasts derived from both neuroﬁbromas (8.4%0.5%
and 19.4%5.5%), and selectively cultured Schwann cells
from a third, smaller neuroﬁbroma (6.7%1.0%). Find-
ings from buccal smears, urine sediment cells, and ﬁbro-
blasts derived from the third neuroﬁbroma were negative
or below the detection limit, as were ﬁndings from blood
from both children of the patient and the control sample
(table 1).
Pigmentary Defects Only (Patient SNF1-2)
Combined NF1 cDNA sequencing and MLPA analysis re-
vealed anNF1microdeletion exclusively present in themel-
anocytes derived from CALMs and the background hyper-
pigmentation area. A second alteration (c.1226_1227del)
was detected only in the melanocytes of the CALM. Fur-
ther characterization of the microdeletion revealed an
atypical deletion, with the proximal breakpoint residing
within the centromeric LCR ﬂanking the NF1 gene and
the distal breakpoint located centromeric of the telomeric
LCR ﬂanking theNF1 gene before JJAZ1 exon 7 (maximum
size of the deletion 1.30 Mb). FISH analysis of skin ﬁbro-
blasts (CALM and hyperpigmented and unaffected skin)
with NF1-speciﬁc probes did not show evidence of low-
level mosaicism when the detection limit of 7% was taken
into account (table 2). FISH analysis of blood lymphocytes
revealed a slightly increased number of nuclei with evi-
dence of NF1 microdeletion (8 [2%] nuclei with one NF1
locus detected by two-color FISH in a total of 400 evalu-
ated nuclei) (table 2), as compared with the non-NF1 con-
trol lymphocyte sample (0.01; ; binomial test).Pp .050
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Table 3. Overview of NF1 Mutations Revealed by Routine Mutation-
Detection Techniques and Quantitative Assays (FISH and Real-Time qPCR)
in Different Tissues Derived from Mosaic Patient SNF1-3, Presenting with
Neuroﬁbromas and Pigmentary Defects, and from Family Members
Patient and Samplea S100b
NF1
Microdeletion c.23251GrA
Routine FISHc Routine qPCRd
SNF1-3:
Neuroﬁbroma (right hand):
SC F 195%  ND  88.8%8.7%
SC F 195%  ND  67.2%9.5%
Fibroblasts ∼10%  ND  12.3%1.8%
CALM (right hand):
Melanocytes NA  ND  97.1%8.2%
Fibroblasts NA  !7%  2.0%.3%
CALM (left thigh):
Melanocytes NA  ND  71.8%5.5%
Fibroblasts NA  !7%  
CALM (right lower back):
Melanocytes NA  ND  54.9%9.1%
Fibroblasts NA  !7%  
Normal skin (right buttock):
Melanocytes NA  ND  
Fibroblasts NA  !7%  
Blood NA  4%  
Buccal smear NA  ND  
Urine NA  ND  
Hair NA  ND  ND
Mother:
Blood NA  ND  
Father:
Blood NA  ND  
Brother:
Blood NA  ND  
Sister:
Blood NA  ND  
NOTE.— p Mutation detectable;  p mutation not detectable. ND p no data
available.
a Schwann cells (SC) grown with (F) or without (F) forskolin.
b Percentage of cells positive for S100 immunostaining. NA p not applicable.
c Percentage of 400 interphase nuclei with NF1 microdeletion determined by FISH
analysis.
d Percentage mutant alleleSEM determined by real-time qPCR.
Pigmentary Defects and Neuroﬁbromas (Patient SNF1-3)
Analysis of neuroﬁbroma-derived Schwann cells (SC F
and SC F) and melanocytes derived from both the CALM
on the right hand and two CALMs remote from that zone
revealed an identical NF1 mutation (c.23251GrA) lead-
ing to out-of-frame skipping of exon 14, as well as a de-
letion of the otherNF1 allele. For all samples, the proximal
deletion breakpoint resided between rs6505129 (chro-
mosome 17 reference position 24777972 [National Center
for Biotechnology Information build 36.2]) and rs6505165
(position 25598975), whereas the distal deletion break-
point resided between the most distal PSV in the telo-
meric NF1 LCR (position 27439522) and rs9904537 (po-
sition 27579216) (minimum/maximum size of deletion
1.84 Mb/2.80 Mb). To test the inﬂuence of excess wild-
type transcript on detection of the mutant transcript
(c.23251GrA), a 5-point 10-fold dilution series of the
mutant form (5#105—50 molecules) was mixed with ex-
cess wild-type (5#105 molecules). Equal amounts of water
(instead of wild-type transcript) were added to a second
series of dilutions. Comparison of both ampliﬁcationplots
revealed that, at low levels of mutant transcript (!1,250
molecules), the presence of the wild-type transcript sig-
niﬁcantly impaired accurate quantiﬁcation of the low-
abundance mutated transcript. Therefore, the sensitivity
of the quantitative assay is estimated at 1/400. Real-time
qPCR demonstrated the presence of the intragenic NF1
mutation (mutant allele percentageSEM) in ﬁbroblasts
derived from both the neuroﬁbroma (12.3%1.8%) and
the CALM on the right hand (2.0%0.3%). Findings from
melanocytes and ﬁbroblasts derived from normal skin, ﬁ-
broblasts derived from both CALMs on the left thigh and
right lower back, peripheral blood, buccal smear, urine
sediment cells, and the control sample were negative. As
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expected, the mutation could not be detected in periph-
eral blood from the parents and siblings of the patient
(table 3). FISH analysis of skin ﬁbroblasts (CALM and un-
affected skin) with NF1-speciﬁc probes did not show evi-
dence of low-level mosaicism when the detection limit of
7%was taken into account (table 3). FISH analysis of blood
lymphocytes revealed a signiﬁcantly increased number of
nuclei with evidence of NF1 microdeletion (15/400 [4%])
(table 3) as compared with the non-NF1 control lympho-
cyte sample (0.01; ; binomial test). Immuno-Pp .000017
ﬂuorescence staining revealed S100-positive cells in the
SC F (195%), SC F (195%), and ﬁbroblast (∼10%) cul-
tures derived from the neuroﬁbroma.
Discussion
In this study, three patients with mosaic NF1 with differ-
ent clinical manifestations were investigated at the mo-
lecular level to provide insight into the cell types andmu-
tational mechanisms involved in the development of
particular NF1-related disease features.
Neuroﬁbromas Only (Patient SNF1-1)
In selectively cultured Schwann cells (SC F) derived from
two neuroﬁbromas, an identical NF1 mutation, in addi-
tion to two tumor-speciﬁc alterations on the other allele,
was detected, clearly conﬁrming the tumor-initiating
properties of Schwann cells in neuroﬁbroma develop-
ment.11,24,25 Quantitative mutation screening of ﬁbroblasts
derived from both neuroﬁbromas revealed only low per-
centages of mutant (ﬁrst-hit) allele (8.4%0.5% and
19.4%5.5%), which is undetectable by conventional
mutation-detection techniques (i.e., PCRNF1 exon 13 and
subsequent sequencing), and might reﬂect contamination
of the ﬁbroblast culture with Schwann cells (see patient
SNF1-3). Similarly, Shultz et al.26 could not demonstrate
any NF1 mutation in neuroﬁbroma-derived ﬁbroblasts
from a patient with segmental NF1 by use of the protein
truncation test, enzymatic mutation detection, and FISH.
Remarkably, only a limited amount of mutant allele
(6.7%1.0%) was detected in selectively cultured Schwann
cells (purity estimated at 195% by S100 staining) from a
third, smaller tumor, further illustrating the high abun-
dance of NF1/ cells in the tumor microenvironment.
A growing body of experimental evidence supports the
idea that NF1 haploinsufﬁciency in the tumor environ-
ment promotes (plexiform) neuroﬁbroma formation in
mice.27–31 Haploinsufﬁcient mast cells, for example,
have been shown to be hypermigratory and to have in-
creased survival and proliferation potential in response to
SCF secreted by Nf1/ Schwann cells.28,30 Whether the
abundance of NF1 wild-type cells in (dermal) neuroﬁbro-
mas from patients with segmental NF1 reﬂects a slightly
different pathogenesis or, alternatively, is associated with
the small size of these patients’ tumors (heterozygous
neighboring cells may promote tumor growth more efﬁ-
ciently than wild-type neighboring cells) remains an im-
portant and intriguing question.
Pigmentary Defects Only (Patient SNF1-2)
Combined NF1 cDNA sequencing and MLPA analysis re-
vealed an NF1 microdeletion exclusively present in mel-
anocytes derived from affected skin of patient SNF1-2
(table 2). Although a high frequency of mosaic NF1 mi-
crodeletions are caused by somatic recombination of
the JJAZ1 gene,32 the current NF1 lesion does not re-
present a typical type II deletion. A second alteration
(c.1226_1227del) was present only inmelanocytes derived
from the CALM but not in the hyperpigmented back-
ground area. Previously, Eisenbarth et al.33 did not detect
somatic NF1 inactivation in melanocytes cultured from
10 CALMs of patients with classic NF1. The discrepancy
with the current data can probably be explained by dif-
ferent melanocyte culture conditions and by the fact that,
in the previous report, the cells were analyzed only for
LOH at the NF1 locus, whereas we performed a compre-
hensive NF1 mutation screening. Available evidence sug-
gests that paracrine cytokines interacting between epi-
dermal melanocytes and nonmelanocytic cells in the skin
play a central role in epidermal hyperpigmentation (re-
viewed by Imokawa34). Although the etiopathogenesis of
NF1-related pigmentary lesions remains largely unknown,
it has been postulated that the mechanism of epidermal
hyperpigmentation and mast cell inﬁltration in NF1
CALMs might be associated with increased secretion of
cytokines such as SCF and hepatocyte growth factor by
dermal ﬁbroblasts.35 Along the same line, De Schepper et
al.36 reported increased levels of soluble SCF in ﬁbroblast
supernatant fromNF1 CALMbut, importantly, also inNF1
normal skin compared with control individuals. In other
words, paracrine networks are at play in the NF1 skin but
are not sufﬁcient for CALM development. Here, we dem-
onstrate that biallelic NF1 inactivation in themelanocytes
may be required for CALM formation, whereas, even in
the haploinsufﬁcient state, the NF1 gene presumably has
an effect on general skin pigmentation. Recently, a sig-
niﬁcant increase in melanocyte density was demonstrated
in NF1 CALM skin compared with NF1 normal skin, con-
trol normal skin, and control CALM skin.36 These NF1
CALM melanocytes also display a higher melanin content
and melanogenesis.37 In light of our current ﬁndings, it is
tempting to speculate that biallelic NF1 inactivation in
melanocytes might be the underlying molecular mecha-
nism for the distinct properties of these NF1-related pig-
mentary lesions. In a next step, it will be essential to de-
termine the dysregulating consequences of neuroﬁbromin
loss and NF1 haploinsufﬁciency on signaling pathways in
melanocytes. Previous studies on segmental pigmentary
lesions revealed NF1 mutations in 9% and 18% of
ﬁbroblasts6,7 and in 20% of keratinocytes7 cultured from
CALMs. In this study, FISH analysis of ﬁbroblasts derived
from the hyperpigmentary and CALM skin lesions of pa-
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tient SNF1-2 was unable to show an NF1 microdeletion
(table 2). Therefore, we speculate that pigmentary lesions
can arise within an environment consisting of predomi-
nantly NF1 wild-type cells.
Interestingly, inactivation of the NF1 gene has been
demonstrated elsewhere in sporadic malignant melano-
ma cell lines38,39 and recently also in an early-disease-stage
melanoma arising in a 15-year-old patient with NF1.40 Al-
though a deﬁnite association between malignant mela-
noma and NF1 has not yet been established, these data
suggest that the NF1 gene acts as a tumor suppressor gene
in melanocytes in benign CALMs as well as in malignant
melanomas.
Pigmentary Defects and Neuroﬁbromas (Patient SNF1-3)
In patient SNF1-3, an NF1 mutation (c.23251GrA) was
revealed in neuroﬁbroma-derived Schwann cells, as well
as in melanocytes derived from both the CALM on the
right hand and two CALMs remote from that zone. More-
over, all samples showed deletion of the other NF1 allele
(1.84 Mb–2.80 Mb). Unfortunately, insufﬁcient material
was available to further pinpoint the deletion breakpoints
by high-resolution techniques. Since melanocytes and
Schwann cells can arise from a bipotent glial-melanocyte
precursor,41 it is possible that one or both NF1 mutations
occurred in a common neural crest precursor. The clinical
observation of neuroﬁbromas arising within an overlying
CALM might be compatible with this hypothesis. In other
words, inactivation of the wild-type NF1 allele at the het-
erozygous NF1 locus in an early developmental stage (e.g.,
neural crest precursor giving rise to bipotent glial-melan-
ocytic cells41) might be responsible for the segmental in-
volvement of epidermis (melanocyte) and several nerve
branches (Schwann cell). Alternatively, a melanocytic pre-
cursor bearing both hits might have migrated to the right
hand area and then locally reversed to glia through a neu-
ral crest–derived glial-melanocytic progenitor.41 Unex-
pectedly, the NF1 point mutation was also detected in
neuroﬁbroma-derived ﬁbroblasts (culture passage 2), al-
beit at a signiﬁcantly lower frequency (12.3%1.8%). Im-
munoﬂuorescence staining demonstrated that the latter
observation most probably can be explained by the pres-
ence of S100-positive cells (Schwann cells and/or mela-
nocytes) in the ﬁbroblast cultures. Quantitative NF1 mu-
tation screening in blood revealed a low percentage of
mosaicism for the NF1 microdeletion only (table 3). This
observation most probably implies that the NF1 micro-
deletion represents the ﬁrst hit. Quantitative mutation
screening also revealed a low percentage of the ﬁrst hit in
blood from patients SNF1-1 and SNF1-2 (tables 1 and 2).
Obviously, these observations raise questions about the
developmental timing of the mutational event and also
the embryological origin of the mutation-bearing cells in
the blood. Possibly, the respective ﬁrst hits might have
occurred in a multipotent stem cell giving rise to neural
crest cells as well as hematopoietic cells. Alternatively,
neural crest stem cells might give rise to a small percentage
of circulating blood cells. It is well established that dif-
ferent cutaneous neuroﬁbromas from the same patient
with NF1 bear different second hits (patient SNF1-1 and
patients described elsewhere13). Moreover, these neuroﬁ-
bromas usually become apparent only during the 2nd de-
cade of life.4 Strikingly, both NF1 inactivating events are
the same in the melanocytes derived from the CALMs on
the right hand, the left thigh, and the right lower back.
This ﬁnding is particularly intriguing, given the typical
congenital appearance of many NF1 CALM lesions. It re-
mains to be further explored whether the early presen-
tation of pigmentary NF1 signs could be attributed to bial-
lelic NF1 inactivation in melanocytic precursors (mela-
noblasts) during embryonic development. Melanoblasts
migrate in mice from the neural crest dorsolaterally and
enter the skin where they proliferate clonally and ﬁnally
differentiate into mature skin melanocytes.42,43 Onemight
assume that neuroﬁbromin loss inmelanoblasts will result
in enhanced proliferation and, hence, increased mela-
nocyte density36 in NF1-related CALM lesions. It will be
essential to molecularly dissect more CALM lesions de-
rived from different areas of the body and to determine
the (presumably different) second hit in NF1 clinical fea-
tures arising only later in life.
The molecular data obtained from all patients with mo-
saic NF1 described in this article undeniably indicate that
the percentage of the NF1 mutation in non–neural crest–
derived cells is often so low that it would be missed by
routine NF1 screening. This implies that an accurate di-
agnosis for mosaic NF1 can be established only by com-
prehensive screening of those cells responsible for the phe-
notypic NF1-related features—that is, Schwann cells in
neuroﬁbromas and/or melanocytes in pigmentary lesions.
Additionally, screening the relevant cell type in the patient
with mosaic NF1 can provide a molecular marker useful
in the prenatal and presymptomatic diagnostic setting.
This new insight will incontestably facilitate the diagnosis
and counseling of individuals withmosaic NF1.Moreover,
the molecular approaches described in this article might
prove beneﬁcial in those 5% of patients fulﬁlling the NF1
National Institutes of Health clinical criteria but in whom
no constitutional NF1 mutation can be revealed in blood
(e.g., patient SNF1-3). Also, for this particular patient
group, comprehensive screening of NF1 phenotype–re-
lated cell types will facilitate clinical diagnosis and further
genetic follow-up.
In conclusion, we provide—for the ﬁrst time, to our
knowledge—molecular evidence that different NF1 mo-
saic phenotypes result from a postzygotic NF1 mutation
in neural crest–derived cell types. Whereas NF1 deﬁciency
in Schwann cells is essential for neuroﬁbroma develop-
ment, biallelic NF1 inactivation in melanocytes seems to
trigger NF1-related CALM development. In our opinion,
the clinical mosaic phenotype points to cell types that are
irrefutably affected by the somatic NF1 mutation. These
ﬁndings provide important insight into the developmen-
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tal concepts underlying NF1-related disease features and
open avenues for improved diagnosis and genetic coun-
seling for individuals with mosaic NF1.
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